***Background.*** Carbapenem-resistant *Enterobacteriaceae* (CRE) bacteremia has been associated with mortality rates of 50%. The New York/New Jersey (NY/NJ) area has been an epicenter for CRE for over a decade, primarily due to *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* (KPC-*Kp*), but there have been no multi-institutional studies describing the clinical and molecular epidemiology of CRE in this region.

***Methods.*** We reviewed all CRE bacteremia episodes in 2013 (first per patient) at eight institutions in the NY/NJ area and assessed patient characteristics, treatments and outcomes. Carbapenem resistance was defined as non-susceptibility to imipenem or meropenem and CRE isolates underwent multilocus sequence typing (MLST) and PCR for carbapenemase genes. Factors associated with 30-day mortality were identified by logistic regression, including the use of ≥2 CRE-active drugs or a carbapenem in the definitive antimicrobial regimen.

***Results.*** There were 131 patients with CRE bacteremia, of which 111 (85%) were due to *Kp. Bla*~KPC~ was detected in 94% of *Kp* (KPC-3: 48%; KPC-2: 46%), and of these, 88% were ST 258. One *bla*~OXA-48~ and one *bla*~NDM-1~ were also detected. All but 4 patients were adults and the median age was 65. Bacteremia onset occurred more frequently outside of the hospital (34%) than in the ICU (24%), including in 24 patients (18%) whose infection began at home. Forty percent of patients had cancer and 24% had an endoscopic procedure within the previous 30 days. There was a median of 45 hours from bacteremia onset until receipt of an antimicrobial agent to which the CRE tested susceptible. Septic shock occurred within 2 days of bacteremia onset in 36% of patients. The 30-day mortality rate was 46% and there was a median of 10 days from bacteremia onset to death. In multivariate analysis, having a urinary source was associated with decreased mortality (odds ratio \[OR\] = 0.26, *P* = .03), whereas having an unknown source (OR = 3.51, *P* = .04), cancer (OR = 2.67, *P* = .03) and being in an ICU (OR = 3.58, *P* = .02) were associated with increased mortality. Neither the use of combination therapy nor a carbapenem in the definitive regimen was associated with survival.

***Conclusion.*** ST 258 KPC-*Kp* remains the dominant CRE in the NY/NJ area. Despite over a decade of experience with these pathogens, CRE bacteremia is still associated with suboptimal initial therapy and 30-day mortality rates that approach 50%.
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